Anzeige
Mehr »
Login
Dienstag, 03.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Eilmeldung: Goldshores aggressiver Winter-Explorationsplan nimmt Gestalt an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
137 Leser
Artikel bewerten:
(0)

Glucose Health, Inc. (OTC: GLUC) Quarterly Report - Q3 Fiscal 2022

Finanznachrichten News

BENTONVILLE, AR, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) ("Company") is pleased to highlight selected financial information from its third Quarterly Report of Fiscal 2022, for the period ended September 30, 2022, posted today at OTCMarkets.com.

  • Q3 2022 Revenue of $340,681 vs. $234,930 for Q3 2021 = a 45% increase.
  • Q3 2022 Gross Profit of $153,789 vs. $62,032 for Q3 2021 = a 148% increase.
  • Q3 2022 Net Income of $8,091 vs. Q3 2021 Net Loss of $133,160.

The Company additionally advises shareholders and interested investors that a progress report regarding its planned up-listing to the NASDAQ Capital Market® stock exchange is expected to be issued by press release, the week of October 31, 2022.

About Glucose Health, Inc. (OTC: GLUC)

By specializing in producing healthy and delicious beverages nutritionally appropriate1 for the nation's 100+ million2 pre and Type-2 diabetics, and additionally, with its planned launch of a new healthy and delicious soluble fiber infused "ready-to-drink" beverage, formulated to meet the nutritional needs of the 95% of Americans who are considered fiber deficient3, Glucose Health, Inc. is uniquely positioned among all micro-cap beverage companies in America. Glucose Health, Inc. is a publicly traded company with the ticker symbol OTC: GLUC.

For more GLUC news visit: www.glucosehealthinc.com
Like us on Facebook at: www.facebook.com/glucodown

1 For citations visit www.glucodown.com/clinical-data
2 National Diabetes Statistics Review, 2020; Centers for Disease Control and Prevention, Department of Health and Human Services
3 Closing America's Fiber Intake Gap. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124841

Contact:
Murray Fleming
Glucose Health, Inc.
info@glucosehealthinc.com
(479) 802-3827

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and while Glucose Health, Inc. is not subject to the 1934 Securities and Exchange Act, contains forward-looking statements within the meaning Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential, "possible," "probable, "believes," "seeks," "may, "will, "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.


© 2022 GlobeNewswire (Europe)
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.